Spotlight
Memorials
Classifieds
Families First
VCAs
News
Weather
Specialists
Sports
Business
Consumer
Health
Life
Out & About
Login
Breaking News
Trump sues BBC for $10 billion, accusing it of defamation over editing of the president's Jan. 6 speech
Just In
Washington wins NCAA soccer title in OT
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
119.78
-0.62 (-0.51%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 15, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
7,805,070
Open
122.00
Bid (Size)
119.87 (400)
Ask (Size)
121.00 (200)
Prev. Close
120.40
Today's Range
119.39 - 122.98
52wk Range
88.57 - 128.70
Shares Outstanding
1,253,809,440
Dividend Yield
2.64%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Gilead's Experimental Combo Tablet For HIV Treatment Hits Primary Goal
↗
Today 12:15 EST
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
Via
Benzinga
3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains
↗
Today 10:10 EST
Via
MarketBeat
Performance
YTD
+30.4%
+30.4%
1 Month
-3.5%
-3.5%
3 Month
+6.4%
+6.4%
6 Month
+8.1%
+8.1%
1 Year
+30.1%
+30.1%
More News
Read More
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
Today 8:30 EST
From
Gilead Sciences, Inc.
Via
Business Wire
Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak
↗
December 12, 2025
Via
Investor's Business Daily
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
December 12, 2025
From
Equity Insider
Via
GlobeNewswire
Gilead Sciences Inc. (NASDAQ:GILD) Presents a Compelling Profile for Value Investors
↗
December 12, 2025
Via
Chartmill
3 Profitable Stocks We Keep Off Our Radar
December 10, 2025
Via
StockStory
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
December 09, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
What Does the Market Think About Gilead Sciences Inc?
↗
December 08, 2025
Via
Benzinga
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
December 07, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
December 06, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
December 06, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
3 Unpopular Stocks We Think Twice About
December 03, 2025
Via
StockStory
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away
↗
December 03, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing
↗
December 01, 2025
Via
MarketBeat
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
↗
November 28, 2025
Via
Benzinga
Top S&P500 movers in Friday's session
↗
November 28, 2025
Via
Chartmill
These S&P500 stocks are moving in today's session
↗
November 28, 2025
Via
Chartmill
Gapping S&P500 stocks in Friday's session
↗
November 28, 2025
Via
Chartmill
Kymera (KYMR) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
Via
The Motley Fool
Topics
Earnings
Gilead Sciences Inc (NASDAQ:GILD) Demonstrates Strong Dividend Reliability and Profitability
↗
November 25, 2025
Via
Chartmill
Gilead Foundation Commits Over $3 Million to Address Food Insecurity
November 24, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today
↗
November 20, 2025
Via
Benzinga
Gilead Sciences Inc Chart Analysis
↗
November 19, 2025
Via
Talk Markets
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
↗
November 19, 2025
Via
Benzinga
Frequently Asked Questions
Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 119.78
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 12/15/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 150.18B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 150B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.